Duality Biotherapeutics is a clinical-stage biotech company dedicated to the discovery and development of next-generation ADC to treat cancer and autoimmune diseases.
The company has successfully built several cutting-edge ADC technology platforms with global intellectual property rights. Leveraging a robust pipeline, the company is conducting multiple global clinical trials across 17 countries, has enrolled over 2000 patients for multiple clinical-stage ADC candidates.
With regard to this listing application, CIPCS Group is honoured to be engaged in providing valuation services related to preferred stock, employee stock option and intangible asset impairment testing for financial reporting purposes.
Congratulations again to Duality Biotherapeutics, Inc.(9606.HK) on its successful listing. The issue price is HKD 94.6 per share, and the amount of funds raised is HKD 1.51 billion.